Welcome to our dedicated page for Cti Biopharma news (Ticker: CTIC), a resource for investors and traders seeking the latest updates and insights on Cti Biopharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cti Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cti Biopharma's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
CTI BioPharma Corp. (Nasdaq: CTIC) announced its participation in two key investor conferences in April 2023, aimed at discussing its novel targeted therapies for blood-related cancers. The company will engage in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 3:45 p.m. ET, and will present at the Stifel 2023 Targeted Oncology Days on April 26, 2023, at 1:00 p.m. ET. Live and archived webcasts can be accessed through the CTI BioPharma website. CTI BioPharma is also noted for its FDA-approved product, VONJO® (pacritinib), which targets myelofibrosis patients with low platelet counts.
CTI BioPharma Corp. (Nasdaq: CTIC) announced on April 10, 2023, that its Compensation Committee granted equity inducement awards to two new employees. This was done under Nasdaq Listing Rule 5635(c)(4) and outside of the company's Amended and Restated 2017 Equity Incentive Plan.
The awards totaled options for 36,000 shares of CTIC common stock, with an exercise price equal to the closing price on each grant date. The options will vest over four years, contingent on continued employment, and are valid for a ten-year term.
CTI BioPharma focuses on targeted therapies for blood-related cancers and has one FDA-approved product, VONJO (pacritinib), aimed at treating patients with specific myelofibrosis conditions.